Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
Journal article published in 2024 by
James K. Godfrey 
,
Lei Gao,
Geoffrey Shouse ,
Joo Y. Song,
Stacy Pak,
Brian Lee ,
Bihong T. Chen,
Avyakta Kallam,
John H. Baird ,
Guido Marcucci,
Lucy Y. Ghoda,
Stephanie Vauleon,
Alexey V. Danilov,
Alex F. Herrera ,
Larry W. Kwak
and other authors.
,
Lei Gao,
Geoffrey Shouse ,
Joo Y. Song,
Stacy Pak,
Brian Lee ,
Bihong T. Chen,
Avyakta Kallam,
John H. Baird ,
Guido Marcucci,
Lucy Y. Ghoda,
Stephanie Vauleon,
Alexey V. Danilov,
Alex F. Herrera ,
Larry W. Kwak
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Although CD20xCD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces responses in CNS lymphoma.